SG11201903061YA - Combination treatments comprising administration of imidazopyrazinones - Google Patents
Combination treatments comprising administration of imidazopyrazinonesInfo
- Publication number
- SG11201903061YA SG11201903061YA SG11201903061YA SG11201903061YA SG11201903061YA SG 11201903061Y A SG11201903061Y A SG 11201903061YA SG 11201903061Y A SG11201903061Y A SG 11201903061YA SG 11201903061Y A SG11201903061Y A SG 11201903061YA SG 11201903061Y A SG11201903061Y A SG 11201903061YA
- Authority
- SG
- Singapore
- Prior art keywords
- valby
- lundbeck
- ottiliavej
- international
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIP0 I PCT 0111111010 0111 °nolo olomEmoimiliflo oimIE (10) International Publication Number WO 2018/078042 Al (51) International Patent Classification: A61K 31/4188 (2006.01) A61P 25/18 A61K 31/4985 (2006.01) A61P 25/24 A61P 25/14 (2006.01) A61P 25/28 A61P 25/16 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (2006.01) KM, ML, MR, NE, SN, TD, TG). (2006.01) (2006.01) Published: — with international search report (Art. 21(3)) W O 20 18/07 80 42 Al (21) International Application Number: PCT/EP2017/077503 (22) International Filing Date: 26 October 2017 (26.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PA201600660 28 October 2016 (28.10.2016) DK (71) Applicant: H. LUNDBECK A/S [DK/DK]; Ottiliavej 9, 2500 Valby (DK). (72) Inventors: KEHLER, Jan; c/o H. Lundbeck A/S, Ot- tiliavej 9, 2500 Valby (DK). RASMUSSEN, Lars, Ky- hn; c/o H. Lundbeck A/S, Ottiliavej 9, 2500 Valby (DK). LANGGARD, Morten; c/o H. Lundbeck A/S, Ottiliavej 9, 2500 Valby (DK). JESSING, Mikkel; c/o H. Lundbeck A/ S, Ottiliavej 9, 2500 Valby (DK). VITAL, Paulo, Jorge, Vieira; c/o H. Lundbeck A/S, Ottiliavej 9, 2500 Valby (DK). JUHL, Karsten; c/o H. Lundbeck A/S, Ottiliavej 9, 2500 Valby (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES (57) : The present invention provides combination treatments comprising administration of compounds that are PDE1 en- zyme inhibitors and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disease, Parkinson's Disease or Huntington's Disease. Separate aspects of the invention are directed to the combined use of said compounds for the treatment of neurodegenerative and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of neurodegenerative disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201600660 | 2016-10-28 | ||
PCT/EP2017/077503 WO2018078042A1 (en) | 2016-10-28 | 2017-10-26 | Combination treatments comprising administration of imidazopyrazinones |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903061YA true SG11201903061YA (en) | 2019-05-30 |
Family
ID=60302087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903061YA SG11201903061YA (en) | 2016-10-28 | 2017-10-26 | Combination treatments comprising administration of imidazopyrazinones |
Country Status (18)
Country | Link |
---|---|
US (1) | US10912773B2 (en) |
EP (1) | EP3532053A1 (en) |
JP (1) | JP2020500841A (en) |
KR (1) | KR20190077349A (en) |
CN (1) | CN109803653A (en) |
AR (1) | AR109990A1 (en) |
AU (1) | AU2017350477A1 (en) |
BR (1) | BR112018013084A2 (en) |
CA (1) | CA3041595A1 (en) |
CL (1) | CL2019001092A1 (en) |
CO (1) | CO2019002889A2 (en) |
IL (1) | IL265633B (en) |
MA (1) | MA46621A (en) |
MX (1) | MX2019004859A (en) |
RU (1) | RU2019108717A (en) |
SG (1) | SG11201903061YA (en) |
WO (1) | WO2018078042A1 (en) |
ZA (1) | ZA201902090B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201629064A (en) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | Triazolopyrainones as PDE1 inhibitors |
JO3627B1 (en) | 2015-04-30 | 2020-08-27 | H Lundbeck As | Imidazopyrazinones as PDE1 inhibitors |
TWI729109B (en) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 1,5-DIHYDRO-4H-PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-c]PYRIDIN-4-ONES AS PDE1 INHIBITORS |
US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
PL3532064T3 (en) | 2016-10-28 | 2020-11-16 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
MA46621A (en) | 2016-10-28 | 2021-06-02 | H Lundbeck As | COMBINATION TREATMENTS INCLUDING THE ADMINISTRATION OF IMIDAZOPYRAZINONES |
WO2019151274A1 (en) | 2018-02-01 | 2019-08-08 | 日本たばこ産業株式会社 | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes |
GB202018412D0 (en) * | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
WO2024042480A1 (en) | 2022-08-26 | 2024-02-29 | Suven Life Sciences Limited | Heteroaromatic compounds for the treatment of neurological disorders |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
DE19709877A1 (en) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-dihydro-pyrazolo [3,4-d] pyrimidinone derivatives |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
DE10238722A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives |
DE10238724A1 (en) | 2002-08-23 | 2004-03-04 | Bayer Ag | New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance |
DE10238723A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl substituted pyrazolyprimidines |
JP2006525966A (en) | 2003-05-09 | 2006-11-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 6-cyclylmethyl- and 6-alkylmethyl substituted pyrazolopyrimidines |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
US20080194592A1 (en) | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
JP5837278B2 (en) | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | New use |
NZ580904A (en) | 2007-05-11 | 2012-02-24 | Pfizer | Amino-heterocyclic compounds for inhibiting pde9 |
US20090143391A1 (en) | 2007-11-30 | 2009-06-04 | Norbert Hofgen | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
WO2010026214A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
JP5813511B2 (en) | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | Organic compounds |
TWI404721B (en) | 2009-01-26 | 2013-08-11 | Pfizer | Amino-heterocyclic compounds |
CA3120504A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
CN103068848B (en) | 2010-08-12 | 2015-11-25 | 伊莱利利公司 | Anti-N3pGlu A BETA antibody and uses thereof |
EP2619208B1 (en) | 2010-09-20 | 2016-11-09 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
JO3089B1 (en) | 2010-11-19 | 2017-03-15 | H Lundbeck As | Imidazole derivatives as PDE10A enzyme inhibitors |
WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
JP6051210B2 (en) | 2011-06-10 | 2016-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | Organic compounds |
MA37958B1 (en) * | 2011-10-10 | 2018-10-31 | H Lundbeck As | Pde9i having an imidazo pyrazinone skeleton |
EP3178820B1 (en) | 2012-01-26 | 2017-12-20 | H. Lundbeck A/S | Pde9- inhibitors with imidazo triazinone backbone |
MX357320B (en) | 2012-06-18 | 2018-07-04 | Dart Neuroscience Cayman Ltd | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds. |
US9073936B2 (en) | 2013-03-15 | 2015-07-07 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP5783297B2 (en) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | Mechanical quantity sensor |
UA117695C2 (en) | 2014-02-19 | 2018-09-10 | Х. Луннбек А/С | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease |
JP5797815B1 (en) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | Post-installed anchor and its construction method |
TWI599358B (en) | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | Combination therapy |
US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
TW201629064A (en) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | Triazolopyrainones as PDE1 inhibitors |
JO3458B1 (en) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2-Amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
MA40941A (en) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-AMINO-5,5-DIFLUORO-6- (FLUOROMETHYL) -6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS |
CR20170187A (en) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for the treatment of Alzheimer's disease |
US20180044343A1 (en) | 2015-03-16 | 2018-02-15 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
JO3627B1 (en) | 2015-04-30 | 2020-08-27 | H Lundbeck As | Imidazopyrazinones as PDE1 inhibitors |
JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
EP3334720A1 (en) | 2015-08-12 | 2018-06-20 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors |
TWI609870B (en) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1 inhibitor |
TWI729109B (en) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 1,5-DIHYDRO-4H-PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-c]PYRIDIN-4-ONES AS PDE1 INHIBITORS |
MX2018014612A (en) * | 2016-06-23 | 2019-03-01 | Avent Inc | Echogenic coil member for a catheter assembly. |
JP2018076285A (en) | 2016-09-14 | 2018-05-17 | 大日本住友製薬株式会社 | Pharmaceuticals containing bicyclic imidazolo derivatives |
US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
MA46621A (en) | 2016-10-28 | 2021-06-02 | H Lundbeck As | COMBINATION TREATMENTS INCLUDING THE ADMINISTRATION OF IMIDAZOPYRAZINONES |
PL3532064T3 (en) | 2016-10-28 | 2020-11-16 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
-
2017
- 2017-10-26 MA MA046621A patent/MA46621A/en unknown
- 2017-10-26 BR BR112018013084A patent/BR112018013084A2/en not_active IP Right Cessation
- 2017-10-26 US US16/345,157 patent/US10912773B2/en active Active
- 2017-10-26 SG SG11201903061YA patent/SG11201903061YA/en unknown
- 2017-10-26 MX MX2019004859A patent/MX2019004859A/en unknown
- 2017-10-26 KR KR1020197011560A patent/KR20190077349A/en not_active Application Discontinuation
- 2017-10-26 CA CA3041595A patent/CA3041595A1/en not_active Abandoned
- 2017-10-26 CN CN201780063188.6A patent/CN109803653A/en active Pending
- 2017-10-26 AU AU2017350477A patent/AU2017350477A1/en not_active Abandoned
- 2017-10-26 WO PCT/EP2017/077503 patent/WO2018078042A1/en unknown
- 2017-10-26 RU RU2019108717A patent/RU2019108717A/en not_active Application Discontinuation
- 2017-10-26 JP JP2019522586A patent/JP2020500841A/en active Pending
- 2017-10-26 EP EP17797276.7A patent/EP3532053A1/en not_active Withdrawn
- 2017-10-27 AR ARP170102996A patent/AR109990A1/en unknown
-
2019
- 2019-03-26 IL IL265633A patent/IL265633B/en active IP Right Grant
- 2019-03-27 CO CONC2019/0002889A patent/CO2019002889A2/en unknown
- 2019-04-03 ZA ZA2019/02090A patent/ZA201902090B/en unknown
- 2019-04-22 CL CL2019001092A patent/CL2019001092A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2019108717A3 (en) | 2021-01-29 |
IL265633B (en) | 2021-05-31 |
EP3532053A1 (en) | 2019-09-04 |
KR20190077349A (en) | 2019-07-03 |
CO2019002889A2 (en) | 2019-06-19 |
US10912773B2 (en) | 2021-02-09 |
CA3041595A1 (en) | 2018-05-03 |
CN109803653A (en) | 2019-05-24 |
MX2019004859A (en) | 2019-06-20 |
BR112018013084A2 (en) | 2018-12-11 |
IL265633A (en) | 2019-05-30 |
AU2017350477A1 (en) | 2019-04-18 |
RU2019108717A (en) | 2020-11-30 |
WO2018078042A1 (en) | 2018-05-03 |
JP2020500841A (en) | 2020-01-16 |
ZA201902090B (en) | 2020-10-28 |
MA46621A (en) | 2021-06-02 |
AR109990A1 (en) | 2019-02-13 |
CL2019001092A1 (en) | 2019-07-05 |
US20190282572A1 (en) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201810117WA (en) | Human platelet lysate derived extracellular vesicles for use in medicine | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201903770UA (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201902531QA (en) | Liquid pharmaceutical composition | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases |